Race Oncology (ASX:RAC) began patient enrollment at Southside Cancer Care Center in Miranda, New South Wales for the Phase 1 clinical trial of RC220 in advanced solid tumors, according to a Thursday filing with the Australian bourse.
It will use ascending doses of RC220 in up to 33 patients to determine the safety, tolerability, pharmacokinetics, maximum tolerated combined dose in combination with doxorubicin, and effects on a range of clinical biomarkers, the filing stated.
The open-label phase one trial will be conducted across multiple sites in Australia, Hong Kong, and South Korea, per the filing.
Race Oncology's shares were up 6% in recent trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。